Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent form of chronic liver disease
that poses challenges in diagnosis and risk stratification. Non-alcoholic steatohepatitis …

Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a
consequence of failed early detection. Professional societies recommend semi‐annual HCC …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Objective A simple combined score with liver stiffness, controlled attenuation parameter and
serum aspartate aminotransferase (AST), the FibroScan-AST (FAST) score, has been …

Non-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a
leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at …

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic
liver disease worldwide, with increasing incidence and prevalence in the setting of the …

Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease
(NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its …

Non-alcoholic fatty liver disease (NAFLD), and its progressive form, non-alcoholic
steatohepatitis (NASH), represent, nowadays, real challenges for the healthcare system …

Aims/hypothesis We aimed to determine whether the use of glucagon-like peptide-1
receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) …

Nonalcoholic fatty liver disease (NAFLD) affects up to one‐third of the US population.
Approximately one‐fifth of patients with NAFLD have nonalcoholic steatohepatitis (NASH) …